1 result(s) for
|PI Name||Protocol #||Title|
|Elie Traer||STUDY00020009||A Multicenter, Phase 1, open-label study of the FGFR inhibitor pemigatinib (INCB054828) administered after chemotherapy in newly diagnosed Acute Myeloid Leukemia (AML) with adverse or intermediate risk cytogenetics|
You may also qualify for Phase 1 Program trials.
For more information: